These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73. Ipilimumab treatment associated with myasthenic crises and unfavorable disease course. Derle E; Benli S Neurol Sci; 2018 Oct; 39(10):1773-1774. PubMed ID: 29948466 [TBL] [Abstract][Full Text] [Related]
74. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Lee B; Wong A; Kee D; Neeson P; Shackleton M; McArthur G; Sandhu S Ann Oncol; 2016 Jun; 27(6):1174-1177. PubMed ID: 26861600 [No Abstract] [Full Text] [Related]
75. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma. Adler NR; Murray WK; Brady B; McCormack C; Pan Y Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853 [No Abstract] [Full Text] [Related]
76. Ipilimumab-induced hypophysitis and ileocolitis: Serial pituitary MRI findings. Singh D; Hsu CC; Kwan GN; Bhuta S Neurol India; 2017; 65(1):165-166. PubMed ID: 28084260 [No Abstract] [Full Text] [Related]
77. Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy. Tietze JK; Angelova D; Heppt MV; Ruzicka T; Berking C Exp Dermatol; 2017 Jul; 26(7):622-629. PubMed ID: 27892653 [TBL] [Abstract][Full Text] [Related]
78. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993 [TBL] [Abstract][Full Text] [Related]
79. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071 [No Abstract] [Full Text] [Related]
80. Ipilimumab for relapse after allogeneic transplantation. Baker H Lancet Oncol; 2016 Sep; 17(9):e374. PubMed ID: 27452141 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]